Ophthalmic complications in Systemic Lupus Erythematosus (SLE) are broad and can occur in up to a third of patients. The British Isles Lupus Assessment Group (BILAG) 2004 Index identifies 13 ocular manifestations of active SLE, as opposed to those related to previous disease activity and/or the consequences of therapy. We conducted a systematic review of published literature to determine the frequency of ophthalmic manifestations of active SLE.
Methods
A systematic literature search of Ovid MEDLINE and EMBASE from their respective inceptions to July 2020 was conducted to identify cohort, case–control and cross-sectional studies.
Results
22 studies meeting eligibility criteria were included. Most studies featured small sample sizes and were judged to have a high risk of methodological bias. The number and quality of studies did not allow us to confidently estimate the incidence of the conditions. No studies reported epidemiological data for orbital inflammation/myositis/proptosis. The prevalence of each of the other ocular manifestations, with the exception of retinal vaso-occlusive disease, was consistently less than 5%. Retinal vasculitis, uveitis and isolated cotton wool spots tended to be associated with more active SLE disease.
Conclusion
The prevalence of eye disease due to SLE activity is uncommon, but clinicians should be aware that some conditions tend to be associated with more active systemic disease. Further studies to determine the incidence and risk factors for these ophthalmic manifestations are needed.
DrenkardCLimSS. Update on lupus epidemiology: advancing health disparities research through the study of minority populations. Curr Opin Rheumatol2019; 31: 689–696.
2.
SivarajRRDurraniOMDennistonAK, et al.Ocular manifestations of systemic lupus erythematosus. Rheumatology2007; 46: 1757–1762.
3.
PalejwalaNVWaliaHSYehS. Ocular manifestations of systemic lupus erythematosus: a review of the literature. Autoimmune Dis2012; 2012: 290898.
4.
SymmonsDPCoppockJSBaconPA, et al.Development and assessment of a computerized index of clinical disease activity in systemic lupus erythematosus. QJM: An Int J Med1988; 69: 927–937.
5.
YeeCSFarewellVIsenbergDA, et al.British Isles Lupus Assessment Group 2004 index is valid for assessment of disease activity in systemic lupus erythematosus. Arthritis Rheum2007; 56: 4113–4119.
6.
IsenbergDARahmanAAllenE, et al.BILAG 2004. Development and initial validation of an updated version of the British Isles Lupus Assessment Group's disease activity index for patients with systemic lupus erythematosus. Rheumatology2005; 44: 902–906.
7.
YeeCSFarewellVIsenbergDA, et al.The BILAG-2004 index is sensitive to change for assessment of SLE disease activity. Rheumatology2009; 48: 691–695.
8.
GallagherKViswanathanAOkhraviN. Association of systemic lupus erythematosus with uveitis. JAMA Ophthalmol2015; 133: 1190–1193.
9.
Sainz de la MazaMMolinaNGonzalez-GonzalezLA, et al.Clinical characteristics of a large cohort of patients with scleritis and episcleritis. Ophthalmology2012; 119: 43–50.
10.
AkpekE.ThorneJEQaziFA, et al.Evaluation of patients with scleritis for systemic disease. Ophthalmology2004; 111: 501–506.
11.
JawaharNWalkerJReynoldsJ, et al.Epidemiology of disease-activity related ophthalmological manifestations in Systemic Lupus Erythematosus – a systematic review. PROSPERO: International prospective register of systematic reviews. CRD42020159610. York, United Kingdom: Centre for Reviews and Dissemination, University of York, 2021. https://www.crd.york.ac.uk/prospero/display_record.php?RecordID=159610 (accessed 14 March 2021).
12.
AchtmanJCWerthVP. Pathophysiology of cutaneous lupus erythematosus. Arthritis Res Ther2015; 17: 182. DOI: 10.1186/s13075-015-0706-2.
13.
HeYSawalhaAH. Drug-induced lupus erythematosus: an update on drugs and mechanisms. Curr Opin Rheumatol2018; 30: 490–497.
HochbergMC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum1997; 40: 1725.
16.
PetriMOrbaiAMAlarcónGS, et al.Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus. Arthritis Rheum2012; 64: 2677–2686.
17.
World Health Organization. International Classification of Diseases and Related Health Problems, 10th revision. Geneva, Switzerland: World Health Organization, 2007.
18.
AringerMCostenbaderKDaikhD, et al.2019 European League Against Rheumatism/American College of Rheumatology classification criteria for systemic lupus erythematosus. Ann Rheumatic Diseases2019; 78: 1151–1159.
19.
HepburnAL. The LE cell. Rheumatology2001; 40: 826–827.
DekkersOMVandenbrouckeJPCevallosM, et al.COSMOS-E: Guidance on conducting systematic reviews and meta-analyses of observational studies of etiology. PLoS Med2019; 16: e1002742.
23.
MuellerMD’AddarioMEggerM, et al.Methods to systematically review and meta-analyse observational studies: a systematic scoping review of recommendations. BMC Med Res Methodol2018; 18: 44.
24.
Joanna Briggs Institute. Critical Appraisal Tools [online]. Adelaide, Australia: Faculty of Health and Medical Sciences The University of Adelaide, 2020, https://joannabriggs.org/critical-appraisal-tools (accessed 3 January 2021).
25.
KlejnbergTMoraes JuniorHVJr. Alterações oculares nos pacientes portadores de lúpus eritematoso sistêmico em acompanhamento ambulatorial. Arquivos brasileiros de oftalmologia2006; 69:233–237. [Full article in Portuguese]
26.
CojocaruVMCiurtinCPopM, et al.[Ophthalmological involvement in rheumatic disease]. Oftalmologia2006; 50:56, 61. [Full article in Romanian]
27.
ErmakovaNAAlekberovaZSReshetniakTM, et al.[Retinal vascular lesions in systemic lupus erythematosus and secondary antiphospholipid syndrome]. Vestnik Oftalmologii2005; 121:31–36. [Full article in Russian]
28.
MendesLEGonçalvesJOCostaVPet al.Alterações oculares no lúpus eritematoso sistêmico. Arquivos Brasileiros de Oftalmologia1998; 61:713–716. [Full article in Portuguese]
29.
GawdatGEl-FayoumiDMarzoukH, et al.Ocular manifestations in children with juvenile-onset systemic lupus erythematosus. Semin Ophthalmol2019; 33: 470–476.
30.
Stafford‐BradyFJUrowitzMBGladmanDD, et al.Lupus retinopathy. Arthritis Rheum1988; 31: 1105–1110.
31.
KharelRShahDNSinghD. Role of lupus retinopathy in systemic lupus erythematosus. J Ophthalmic Inflamm Infect2016; 6: 1–4.
32.
SitaulaRNarayan ShahDSinghD. The spectrum of ocular involvement in systemic lupus erythematosus in a tertiary eye care center in Nepal. Ocul Immunol Inflamm2011; 19: 422–425.
33.
Al-MayoufSMAl-HemidanAI. Ocular manifestations of systemic lupus erythematosus in children. Saudi Med J2003; 24: 964–966.
34.
DrososAAPetrisCAPetroutsosGM, et al.Unusual eye manifestations in systemic lupus erythematosus patients. Clin Rheumatol1989; 8: 49–53.
35.
UshiyamaOUshiyamaKKoaradaS, et al.Retinal disease in patients with systemic lupus erythematosus. Ann Rheum Dis2000; 59: 705–708.
36.
YapEYAu EongKGFongKY, et al.Ophthalmic manifestations in Asian patients with systemic lupus erythematosus. Singapore Med J1998; 39: 557–559.
37.
DuboisELTuffanelliDL. Clinical manifestations of systemic lupus erythematosus. Computer analysis of 520 cases. JAMA1964; 190: 104–111.
38.
FrithPBurgeSMMillardPR, et al.External ocular findings in lupus erythematosus: a clinical and immunopathological study. Br J Ophthalmol1990; 74: 163–167.
Domngang NocheCKagmeniGDohvomaV, et al.Ophthalmic manifestations in chronic inflammatory rheumatic diseases at a referral hospital of Yaounde, Cameroon. Ocul Immunology Inflammation2018; 26: 259–264.
41.
SpaethGL. Corneal staining in systemic lupus erythematosus. New Engl J Med1967; 276: 1168–1171.
42.
LevittAEMcManusKTMcClellanAL, et al.Ocular inflammation in the setting of concomitant systemic autoimmune conditions in an older male population. Cornea2015; 34: 762–767.
43.
DammaccoRProcaccioPRacanelliV, et al.Ocular involvement in systemic lupus erythematosus: the experience of two tertiary referral centers. Ocul Immunol Inflamm2018; 26: 1154–1165.
44.
MontehermosoACerveraRFontJ, et al.Association of antiphospholipid antibodies with retinal vascular disease in systemic lupus erythematosus. Semin Arthritis Rheum1999; 28: 326–332.
45.
SethGChengappaKGMisraDP, et al.Lupus retinopathy: a marker of active systemic lupus erythematosus. Rheumatol Int2018; 38: 1495–1501.
46.
KampylafkaEIAlexopoulosHKosmidisML, et al.Incidence and prevalence of major central nervous system involvement in systemic lupus erythematosus: a 3-year prospective study of 370 patients. PLoS One2013; 8: e55843.
47.
GaoNLiMTLiYH, et al.Retinal vasculopathy in patients with systemic lupus erythematosus. Lupus2017; 26: 1182–1189.
48.
KahwagePPFerrianiMPLFurtadoJM, et al.Uveitis in childhood-onset systemic lupus erythematosus patients: a multicenter survey. Clin Rheumatol2017; 36: 547–553.
49.
AletahaDEpsteinAJSkupM, et al.Risk of developing additional immune-mediated manifestations: a retrospective matched cohort study. Adv Ther2019; 36: 1672–1683.
50.
YenYCWengS-FChenH-A, et al.Risk of retinal vein occlusion in patients with systemic lupus erythematosus: a population-based cohort study. Br J Ophthalmol2013; 97: 1192–1196.
51.
WatsonPGHayrehSS. Scleritis and episcleritis. Br J Ophthalmol1976; 60: 163–191.
52.
GuptaYKishoreAKumariP, et al.Peripheral ulcerative keratitis. Surv Ophthalmol2021;66:977–998. doi: 10.1016/j.survophthal.2021.02.013
53.
Hoang-XuanTFosterCSRiceBA. Scleritis in relapsing polychondritis. Ophthalmology1990; 97: 892–898.
54.
WatanabeRIshiiTYoshidaM, et al.Ulcerative keratitis in patients with rheumatoid arthritis in the modern biologic era: a series of eight cases and literature review. Int J Rheum Dis2017; 20: 225–230.
55.
JajodiaS. Clinical study of peripheral ulcerative keratitis. J Evid Based Med Healthc2020; 7: 1699–1704. doi: 10.18410/jebmh/2020/354.
56.
TsiroukiTDastiridouASymeonidisC, et al.A focus on the epidemiology of uveitis. Ocul Immunology Inflammation2018; 26: 2–16.
57.
Standardization of Uveitis Nomenclature (SUN) Working Group. Standardization of uveitis nomenclature for reporting clinical data. Results of the First International Workshop. Am J Ophthalmol2005; 140: 509–516.
58.
SoutoFMGiampietroBVTakiutiJT, et al.Clinical features of paediatric uveitis at a tertiary referral centre in São Paulo, SP, Brazil. Br J Ophthalmol2019; 103: 636–640.
59.
TeixeiraLPAbrahãoMMDáliaER, et al.Study of the prevalence of uveitis in a tertiary ophthalmology hospital in Teresina, Piauí, Brazil. Revista Brasileira de Oftalmologia2016; 75: 174–180.
60.
El-AsrarAMHerbortCPTabbaraKF. A clinical approach to the diagnosis of retinal vasculitis. Int Ophthalmol2010; 30: 149–173.
61.
RodriguezMSivaACrossSA, et al.Optic neuritis: a population-based study in Olrnsted County, Minnesota. Neurology1995; 45: 244–250.
62.
IyerAElsoneLAppletonR, et al.A review of the current literature and a guide to the early diagnosis of autoimmune disorders associated with neuromyelitis optica. Autoimmunity2014; 47: 154–161.
63.
BelskyMAmerHDiaSet al.FRI0583 neuromyelitis optica overlaps frequently with systemic rheumatic diseases in African-Americans: experience at a large US academic medical center. In: Poster Session Presented at: European Congress of Rheumatology 2019, Madrid, Spain, 14 June.
64.
ZhangYZhaoJLLiMT, et al.Clinical characteristics and outcomes of connective tissue disease accompanied neuromyelitis optica spectrum disease in Chinese patients. Mult Scler J2018; 24: 407–408.
65.
HayrehSS. Acute ischemic disorders of the optic nerve: Pathogenesis, clinical manifestations and management. Ophthalmol Clin North Am1996; 9: 407–442.
66.
HayrehSS. Ischaemic optic neuropathy. Indian J Ophthalmol2000; 48: 171–194.
67.
LeeJ-YParkK-AOhSY. Prevalence and incidence of non-arteritic anterior ischaemic optic neuropathy in South Korea: a nationwide population-based study. Br J Ophthalmol2018; 102: 936–941.
68.
MinaRBrunnerHI. Update on differences between childhood-onset and adult-onset systemic lupus erythematosus. Arthritis Research Therapy2013; 15: 218–219.
69.
GreenLVinkerSAmitalH, et al.Pseudotumor cerebri in systemic lupus erythematosus. Semin Arthritis Rheum1995; 25: 103–108.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
